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Telocytes are interstitial cells characterized by small cell bodies with very long and slender 
processes extending from them. They are present in most tissues and are most commonly 
found in close association with nerves, smooth muscle and microvascular networks in tissue 
interstitial space. Telocytes maintain tissue homeostasis in various ways including modulation of 
electrical activity, regulation of stem cell proliferation and angiogenesis. The role of telocytes in 
blood vessels stems from a structural and functional coupling to vascular endothelial and 
smooth muscle cells. This review explores the distribution of telocytes in cardiovascular tissues, 
their mechanisms in angiogenesis and application of this property in tissue regeneration. The 
literature search was conducted on PubMedTM, Science directTM and African Journals Online 
databases as well as Google ScholarTM search engines. The keywords used in the literature 
search included ‘telocytes’, ‘cardiovascular telocytes’, ‘blood vessel’, ‘cardiac tissue’, ‘(neo-
)angiogenesis’ and ‘tissue regeneration’. Articles which contained the keywords and relevant 
citations from their reference lists were included in the study. In conclusion, telocytes display 
close structural relationship with cardiovascular tissues. They play an angiogenesis inducing role 
which may be explored as a therapeutic target in tissue repair and regeneration. 
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INTRODUCTION 
Telocytes are a specialized type of 
interstitial cells characterized in electron 
microscopy by the presence of telopodes, 
which are long slender processes that 
extend from their cell bodies. The term 
‘Telocytes’ was first suggested by Popescu 
et al. (2010) to refer to all interstitial cells of 
Cajal-Like Cells found in other tissues other 
than the gastrointestinal tract. Telocytes are 
ubiquitously distributed in tissues around 
the body and are commonly found in close 
contact with capillaries and other 
microvessels supplying skeletal muscle 
(Marini et al., 2018), skin (Ceafalan et al., 
2012), uterus (Aleksandrovych et al., 2016), 
lung (Zheng et al., 2014a), esophagus 
(Chen et al., 2013), eyes (Luesma et al., 
2013), placenta (Suciu et al., 2010) and 
duodenum (Cantarero et al., 2011). In the 
cardiovascular system, telocytes are found 
in the myocardium of the heart 
(Gherghiceanu and Popescu, 2012) and in 
the walls of larger arteries and veins (Li et 
al., 2014). 
Telocytes display heterocellular connections 
with vascular endothelial cells, smooth 
muscle cells and Schwann cells (Luesma et 
al., 2013). These include point contacts, 
nanocontacts and planar contacts. These 
contacts are atypical intercellular junctions 
characterized by reduced intermembrane 
distance but lacking structural proteins 
associated with classical junctions 
(Gherghiceanu and Popescu, 2012).  The 
role of telocytes in tissue regeneration and 




angiogenesis has been suggested (Bei et 
al., 2015). The telocytes located within the 
extracellular matrix in close connection with 
blood vessels produce angiogenic factors 
such as vascular endothelial growth factor 
(VEGF) and epidermal growth factor (EGF) 
(Zheng et al., 2014a).  These cells also 
demonstrate the presence of measurable 
quantities of proangiogenic microRNAs that 
influence vascular development (Manole et 
al., 2011). These factors are thought to 
cause angiogenesis as is seen in cardiac 
tissue treated with telocyte exosomes 
following vascular injury (Yang et al., 2017).  
Knowledge of the role and mechanisms of 
telocytes in angiogenesis may influence the 
development of therapeutic strategies for 
ischemic diseases such as myocardial 
infarction, stroke, peripheral artery diseases 
and coronary heart diseases. This paper 
provides a summary of the structural 
properties of telocytes in the cardiovascular 
system, their mechanisms in induction of 
angiogenesis and value of this properrty in 
tissue regeneration. 
METHODOLOGY 
The literature search was conducted on 
Google ScholarTM search engines and on 
PubMedTM, Science directTM and African 
Journals Online databases. The keywords 
used in the literature search were 
‘telocytes’, ‘cardiovascular telocytes’, ‘blood 
vessel’, ‘cardiac tissue’, ‘(neo-)angiogenesis’ 
and ‘tissue regeneration’. Articles which 
contained the keywords and information 
relevant to the review were included in the 
study. Any additional papers from the 
reference lists of these articles which were 
noted to be relevant were also included. 
Articles were excluded if they did not focus 
on telocytes and their role in angiogenesis, 
were not accessible for free or not available 
in English. The search carried out on the 
databases mentioned along with relevant 
papers identified in their reference lists 
yielded a total of 40 papers relevant to the 
review which were then reviewed. 
 
 
Figure 1: Photomicrograph showing the structure of 
telocytes in transmission electron microscopy with 
digitally enhanced color (blue). The telopodes are easily 
noticeable (white arrows). (Adapted from Ceefalan et 
al., 2012). 
 






Properties of telocytes in 
cardiovascular system 
Telocytes are closely related to the tissues 
of the cardiovascular system, including the 
heart and blood vessels. These cells are 
present in blood and in walls of large 
arteries and veins. They are located in the 
tunica adventitia of coronary arteries, 
internal thoracic arteries and carotid arteries 
(Li et al., 2014). In the walls of veins, they 
are located in the sub-endothelial layer 
(Zhang, 2016). Telocytes are also located in 
close contact with arterioles and capillaries 
supplying tissues. Investigations using 
transmission electron microscopy show that 
telocytes have two distinguishing features: 
2-5 cell body prolongations referred to as 
telopodes and presence of distinct caveolae 
(Gherghiceanu and Popescu, 2012, 2005). 
Telopodes display a moniliform aspect 
characterized by alternating thin and dilated 
segments referred to as ‘podomers’ and 
‘podoms’ respectively (Ibba-Manneschi et 
al., 2016) [Figure 1].  The dilated regions 
accommodate mitochondria, endoplasmic 
reticulum and caveolae. Telocytes can have 
varying shapes depending on the number of 
their telopodes: piriform for cells with one 
telopodes, spindle for those with two 
telopodes, triangular for those with three or 
stellate for multiple telopodes (Enciu and 
Popescu, 2015).  
Telocytes display direct connections to other 
cell types such as vascular endothelial cells, 
vascular smooth muscle cells and cardiac 
myocytes (Aleksandrovych et al., 2017). 
These connections, located in their 
telopodes, allow them to communicate even 
with distant cells. The junctions include 
point contacts, nanocontacts and planar 
contacts (Gherghiceanu and Popescu, 
2012). These junctions are not similar to 
classical intercellular junctions. This is 
because they lack electron-dense structures 
present on the plasma membrane or 
cytoplasm adjacent to the contacts that 
may give inference to one of the known 
classes of intercellular junctions. The basal 
lamina of both vascular endothelial cells and 
pericytes are diminished at the level of their 
heterocellular junctions with telocytes. 
Areas of contact between telocytes and 
vascular cells may act as points of 
communication or functional coupling (Suciu 
et al., 2010). This direct contact allows 
telocytes to influence the proliferation of 
vascular endothelial and smooth muscle 
cells. In addition, they create a scaffolding 
for support of stem cells that migrate to 
form new vascular cells during angiogenesis 
(Aleksandrovych et al., 2017). 
Role of telocytes in angiogenesis in-
vivo and in-vitro 
i) Evidence of the role of telocytes in 
angiogenesis in tissue microvascular 
network 
Telocytes play a role in cardiac regeneration 
by promoting angiogenesis, as evidenced by 
results from experimental research in 
animals. Transplantation of cardiac 
telocytes has been shown to increase 
vascular density in the myocardium of rats 
with induced myocardial infarction (MI), 
indicating an angiogenesis inducing role 
(Zhao et al., 2014). Telocytes may support 
this process angiogenesis by providing a 
structural and functional niche for 
endothelial cells. Reports have indicated 
that the number of telocytes increases in 
neo-angiogenesis induced by agents such 
as phytochemicals in cardiac tissue affected 
by MI (Nour et al., 2017).  
Li et al. (2016) in a previous study 
demonstrated that the number of telocytes 
significantly increases in vascular walls after 
carotid artery balloon injury in rats. 




Attempts at regeneration of the injured 
tissue showed that the proportion of 
vascular smooth muscle cells in the blood 
vessels increased significantly when 
incubated with supernatant of telocytes (Li 
et al., 2016). This suggests that these cells 
induce proliferation of vascular smooth 
muscle cells and, therefore, play a role  in 
the repair of ischemic injury to the heart.  
Experimental research on pulmonary tissue 
illustrates that telocytes are involved in the 
process of angiogenesis in the 
microvascular network. Expression of VEGF 
and EGF in human lung tissue is 
significantly higher when co-cultured with 
telocytes (Zheng et al., 2014). Telocytes 
also promote the proliferation of human 
pulmonary microvascular endothelial cells. 
They have been shown to cause partial 
recovery in human pulmonary microvascular 
endothelial cells injured by 
lipopolysaccharide (LPS) endotoxin (Zheng 
et al., 2014a). An article by Ma et al. (2018) 
correspondingly indicates that telocytes 
improve the proliferation of pulmonary 
vascular endothelial cells and cause an 
improvement in LPS induced inhibition of 
endothelial cell proliferation. Expression of 
VEGF and angiogenic microRNAs is reported 
to increase in the medium containing LPS, 
with a concomitant increase in the number 
of telocytes. 
In the placenta, VEGF produced by 
telocytes acts as an angiogenic agent in 
promoting endothelial cell proliferation and 
vascular permeability. It also maintains 
newly formed blood vessels in the placenta 
(Suciu et al., 2010). There is a low 
expression of inducible nitric oxide synthase 
in telocytes from normal placentas. This 
implies a  role of telocytes in the regulation 
of placental blood flow through an inhibitory 
signalling pathway that involves nitric oxide 
(Nizyaeva et al., 2018). 
In skeletal muscle, telocytes may be crucial 
in the regulation of blood vessels, blood 
flow and muscle regeneration (Popescu et 
al., 2011). The role of telocytes in 
angiogenesis in skeletal muscle may start as 
early as myogenesis (Marini et al., 2018). 
These cells play a role in inducing 
angiogenesis to support myotube 
maturation and muscle tissue 
differentiation. They support skeletal muscle 
fibre regeneration in postnatal life by 
expressing VEGF for recruitment of small 
vessels and providing scaffolding guidance 
for satellite cells (Bojin et al., 2011; 
Popescu et al., 2011). 
Telocytes in the oesophagus produce 
measurable amounts of VEGF and EGF 
(Chen et al. 2013). Secretion of pro-
angiogenic factors by telocytes and their 
close spatial relations with vascular 
endothelial and smooth muscle cells implies 
their involvement in angiogenesis. Likewise, 
telocytes influence proliferation and 
regulation of blood vessels in the skin 
(Manole and Simionescu, 2016), female 
reproductive tract (Aleksandrovych et al., 
2016), parotid gland (Nicolescu et al., 2012) 
and synovium (Rosa et al., 2018). Further 
studies may however be necessary to 
establish the role of these cells in tissue 
microvascular network in varying 
physiological and pathological states.  
ii) Mechanisms of telocyte induced 
angiogenesis 
Telocytes communicate indirectly with 
vascular endothelial cells and other cells of 
cardiovascular tissues through paracrine 
signalling. This is achieved by secreting 
microvesicles that contain factors such as 
VEGF which regulates vascular proliferation 
(Zheng and Wang, 2016). Cardiac telocytes 
are shown in cultures to release three types 
of extracellular vesicles; multivesicular 
cargos (tightly packed endomembrane 
bound vesicles), exosomes and ectosomes 
(Fertig et al., 2014). These vesicles contain 
secretory products from telocytes, including 
pro-angiogenic factors and microRNAs. 




Cardiac telocytes increase their expression 
of VEGF and the inflammatory protein 
interleukin-6 (IL-6) when co-cultured with 
cardiac stem cells in vitro (Albulescu et al., 
2015). The mechanisms of telocyte induced 
angiogenesis in the heart include the 
expression of stem cell markers and VEGF. 
These are important factors which promote 
vascular smooth muscle and endothelial cell 
development from angioblast stem cells  
(Albulescu et al., 2015).  
VEGF and their receptors are key signalling 
factors that initiate the process of 
angiogenesis (Karamysheva, 2018). The 
production of such angiogenic factors by 
telocytes indicate their important role in the 
development of blood vessels. Telocytes 
also expresses nitric oxide which is an 
important molecule in the development and 
organization of new blood vessels 
(Aleksandrovych et al., 2016). From these 
studies, it can be proposed that telocytes 
participate in angiogenesis, both in 
physiological and pathological conditions. 
Telocytes induce angiogenesis by the 
release of VEGF, microRNAs and other 
angiogenesis promoting factors. These 
increase angioblast differentiation into 
vascular cells and provides a scaffold for the 
migration of these developing cells. 
Role of telocytes in vascular diseases 
Existence of hypoxia and oxidative stress in 
the placenta in women with preeclampsia 
leads to a reduction in the number of 
telocytes and impairment of their function 
(Bosco et al., 2015). This is evidenced by 
morphological changes in telocytes 
including thickening of telopodes and 
decreased the content of endoplasmic 
reticulum (Nizyaeva et al., 2018). Hypoxia 
and oxidative stress may be one of the 
causes of vascular impairment in the 
placenta during pre-eclampsia. Telocytes 
have been revealed not only promote 
angiogenesis but also play a role in 
placental blood flow regulation through 
nitric oxide signalling (Suciu et al., 2010). 
Further exploration of this relationship 
between telocytes and the placental 
microvascular network can improve the 
understanding of the pathology of pre-
eclampsia and intrauterine growth 
restriction. 
In the female reproductive tract, the role of 
telocytes can predict a crucial role in the 
development of uterine leiomyomas, 
endometriosis, salpingitis and cancers 
(Aleksandrovych et al., 2016). Loss of 
uterine telocytes in uterine leiomyoma is 
postulated to be responsible for the 
decreased blood vessel formation observed 
(Varga et al., 2018). This may cause a shift 
to anaerobic metabolism in smooth muscle 
cells, a factor that favours the development 
of leiomyoma. This is consistent with the 
reporting of decreased angiogenesis and 
vascular density by Sajewicz et al. (2016) 
and Uluer et al., (2015) respectively in 
studies investigating uterine leiomyoma 
pathology. 
Neo-angiogenesis is partially responsible for 
some of the clinical signs seen in psoriasis, 
a common skin condition. Evidence of a 
reduction in telocyte density around blood 
vessels in skin affected by psoriasis 
suggests that they may play a role in the 
development of the disease (Manole et al., 
2015). Telocyte expression in perivascular 
tissue, however, improves with the 
application of corticosteroids on the affected 
skin. Phenotypic changes in vascular 
smooth muscle cells not surrounded by 
telocytes in the papillary dermis of psoriatic 
skin partly explains the impairment in blood 
vessel structure in the disease (Manole et 
al., 2015). 
The role of telocytes in other diseases that 
stem from impaired angiogenesis remains 
to be established. Their role in tumour 
stroma formation has been hypothesized to 
be due to the secretion of angiogenic 
inducers, among other factors (Diaz-Flores 




et al., 2016). Rosa et al. (2017) also 
proposed that telocytes can be players in 
the development of degenerative joint 
diseases such as arthritis, lupus and gout. 
These are diseases that exhibit synovial 
inflammation and blood vessel proliferation 
as predominant features.  
Therapeutic  application for angiogenic 
role of telocytes 
Telocytes are not yet used therapeutically 
for vascular injury. However, several studies 
have attempted to establish their benefit in 
animal experimental models for treating 
myocardial infarction. For example, 
transplantation of cardiac telocytes causes 
increased angiogenesis and reduces the 
infarct size in rat experimental models of 
myocardial infarction (Zhao et al., 2014). 
This is associated with an overall 
enhancement of myocardial function as 
shown by higher left ventricle ejection 
fraction. The tissue regeneration due to 
augmented angiogenesis caused by 
transplanted telocytes also occurs without 
excessive fibrosis in heart muscle. Telocytes 
can be utilized to develop novel therapeutic 
targets in tissue engineering and 
regeneration (Aleksandrovych et al., 2017). 
Their angiogenic role in various tissues 
presumably provides a regenerative ability 
which may be used alone or in combination 
with stem cell therapy for treating MI (Boos 
et al., 2016).  
Telocyte therapy can similarly be developed 
in clinical trials for the treatment of lung 
diseases. In vitro experiments have shown 
that telocyte administration causes an 
improvement of function in human 
pulmonary endothelial cells injured by LPS 
(Ma et al., 2018; Zheng et al., 2014a). 
Evidence suggests there is presence of 
telocytes in the limbus and uvea of the eye 
(Luesma et al., 2013). The potential of 
these cells in neo-angiogenesis can be 
explored to generate therapy in neovascular 
eye diseases such as age-related macular 
degeneration (Bei et al., 2015; 
Campochiaro, 2013).  
Formation of mature, well organized and 
stable vasculature is a key goal in tissue 
engineering, regenerative medicine, 
therapeutic angiogenesis and treatment of 
vascular disease (Suciu et al., 2012). 
Regenerative therapy using stem cells alone 
may fail in some cases due to inadequate 
formation of a blood vessel scaffold in the 
newly formed tissues (Pellegrini and 
Popescu, 2011). Stem cells, when co-
administered with telocytes, would provide 
better results for such therapy than when 
administered alone (Popescu et al., 2015). 
This is explained by their ability to induce 
angiogenesis. 
The physiological capacity of telocytes to 
induce the formation of stable vasculature 
may be valuable and remains to be fully 
explored in clinical trials. The role of 
telocytes in supporting angiogenesis as 
shown in animal experiments should be 
tailored to create therapies for the 
regeneration of human tissues (Kucybala et 
al., 2017). These therapies may be used to 
treat diseases in tissues which naturally 
have a low regenerative capacity through 
genetic engineering of telocytes (Boos et 
al., 2016). 
CONCLUSION 
Telocytes have a unique relationship with 
vascular endothelial cells in tissue 
microvasculature as well as endothelial and 
smooth muscle cells in larger vessels. They 
are mechanically coupled with these cells 
through contacts that exist at telopodes. 
They also exhibit paracrine communication 
with these cells via secretion of microRNAs, 
nitric oxide and vascular growth factors 
such as VEGF and EGF which are key 
signalling factors in the process of 
angiogenesis. These cells are linked to the 
pathogenesis of ischemic diseases and 
further experiments may provide new 




strategies in their treatment. The 
angiogenesis inducing role of telocytes may 
be explored as a therapeutic target in tissue 
repair and regeneration e.g. by direct 
transplantation of genetically engineered 
telocytes. 
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